CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

The Lancet Neurology

Volumn 15, Issue 7, 2016, Pages 673-684

  Olsson, Bob ^a   Lautner, Ronald ^a   Andreasson, Ulf ^a   Öhrfelt, Annika ^a   Portelius, Erik ^a   Bjerke, Maria ^a,b   Hölttä, Mikko ^a   Rosén, Christoffer ^a   Olsson, Caroline ^a   Strobel, Gabrielle ^c   Wu, Elizabeth ^c   Dakin, Kelly ^c   Petzold, Max ^a,d   Blennow, Kaj ^a   Zetterberg, Henrik ^a,e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c Alzforum   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; FATTY ACID BINDING PROTEIN 3; GLIAL FIBRILLARY ACIDIC PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; SERUM ALBUMIN; SOLUBLE AMYLOID PRECURSOR PROTEIN ALPHA; SOLUBLE AMYLOID PRECURSOR PROTEIN BETA; TAU PROTEIN; UNCLASSIFIED DRUG; VISININ; VISININ LIKE PROTEIN 1;

ALBUMIN BLOOD LEVEL; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; META ANALYSIS; MICROGLIA; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; PROTEIN METABOLISM; SYSTEMATIC REVIEW; BLOOD; CEREBROSPINAL FLUID;

ALZHEIMER DISEASE; BIOMARKERS; HUMANS;

EID: 84963632368     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(16)00070-3     Document Type: Article

References (34)

1. Blennow, K, de Leon, MJ, Zetterberg, H, Alzheimer's disease. Lancet 368 (2006), 387–403.
2. Salloway, S, Sperling, R, Fox, NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 370 (2014), 322–333.
3. de Souza, LC, Chupin, M, Lamari, F, et al. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. Neurobiol Aging 33 (2012), 1253–1257.
4. Tapiola, T, Alafuzoff, I, Herukka, SK, et al. Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66 (2009), 382–389.
5. Hesse, C, Rosengren, L, Andreasen, N, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297 (2001), 187–190.
6. Ost, M, Nylen, K, Csajbok, L, et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67 (2006), 1600–1604.
7. Buerger, K, Ewers, M, Pirttila, T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 (2006), 3035–3041.
8. Seppala, TT, Nerg, O, Koivisto, AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78 (2012), 1568–1575.
9. Blennow, K, Hampel, H, Weiner, M, Zetterberg, H, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6 (2010), 131–144.
10. Schott, JM, Petersen, RC, New criteria for Alzheimer's disease: which, when and why?. Brain 138 (2015), 1134–1137.
11. Sutphen, CL, Fagan, AM, Holtzman, DM, Progress update: fluid and imaging biomarkers in Alzheimer's disease. Biol Psychiatry 75 (2014), 520–526.
12. Liberati, A, Altman, DG, Tetzlaff, J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
13. McKhann, G, Drachman, D, Folstein, M, Katzman, R, Price, D, Stadlan, EM, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
14. Friede, RL, Samorajski, T, Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167 (1970), 379–387.
15. Schmechel, D, Marangos, PJ, Zis, AP, Brightman, M, Goodwin, FK, Brain endolases as specific markers of neuronal and glial cells. Science 199 (1978), 313–315.
16. Laterza, OF, Modur, VR, Crimmins, DL, et al. Identification of novel brain biomarkers. Clin Chem 52 (2006), 1713–1721.
17. Ockner, RK, Manning, JA, Poppenhausen, RB, Ho, WK, A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science 177 (1972), 56–58.
18. Bonneh-Barkay, D, Bissel, SJ, Wang, G, et al. YKL-40, a marker of simian immunodeficiency virus encephalitis, modulates the biological activity of basic fibroblast growth factor. Am J Pathol 173 (2008), 130–143.
19. Horbinski, C, Wang, G, Wiley, CA, YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas. Int J Clin Exp Pathol 3 (2010), 226–237.
20. Ishizuka, K, Kimura, T, Igata-yi, R, Katsuragi, S, Takamatsu, J, Miyakawa, T, Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease. Psychiatry Clin Neurosci 51 (1997), 135–138.
21. Brenner, M, Johnson, AB, Boespflug-Tanguy, O, Rodriguez, D, Goldman, JE, Messing, A, Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 27 (2001), 117–120.
22. Olsson, B, Zetterberg, H, Hampel, H, Blennow, K, Biomarker-based dissection of neurodegenerative diseases. Prog Neurobiol 95 (2011), 520–534.
23. Whiting, P, Rutjes, AW, Dinnes, J, Reitsma, J, Bossuyt, PM, Kleijnen, J, Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 8 (2004), 1–234.
24. Bossuyt, PM, Reitsma, JB, Bruns, DE, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 138 (2003), W1–12.
25. Shea, BJ, Grimshaw, JM, Wells, GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol, 7, 2007, 10.
26. Mattsson, N, Andreasson, U, Persson, S, et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 9 (2013), 251–261.
27. Armitage, P, Colton, T, (eds.) Encyclopedia of Biostatistics Chichester, 1998, John Wiley & Sons, London, 3731–3737.
28. Friedrich, JO, Adhikari, NK, Beyene, J, The ratio of means method as an alternative to mean differences for analyzing continuous outcome variables in meta-analysis: a simulation study. BMC Med Res Methodol, 8, 2008, 32.
29. DerSimonian, R, Laird, N, Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
30. Jensen, M, Schroder, J, Blomberg, M, et al. Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression. Ann Neurol 45 (1999), 504–511.
31. Osorio, RS, Gumb, T, Pomara, N, Soluble amyloid-beta levels and late-life depression. Curr Pharm Des 20 (2014), 2547–2554.
32. Buchhave, P, Minthon, L, Zetterberg, H, Wallin, AK, Blennow, K, Hansson, O, Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69 (2012), 98–106.
33. Bateman, RJ, Xiong, C, Benzinger, TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367 (2012), 795–804.
34. Jansen, WJ, Ossenkoppele, R, Knol, DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313 (2015), 1924–1938.